MONTREAL --
Many in the international science community reacted with disappointment and not a little frustration on Wednesday, after finally seeing statistical data from a study on the effectiveness of medication colchicine.
“We can confirm that the primary outcome was not statistically significant,” said Dr. Emily McDonald a scientist at the MUHC’s Research Institute.
The anti-inflammatory drug, now used to treat gout was touted by the Montreal Heart Institute just days ago in a press release, as an effective oral medication for non-hospitalized COVID-19 patients. In a Friday press release, the MHI researchers claimed the drug reduced the risk of death or hospitalization for COVID-19 by 21 per cent.